4 completed, 3 unknown, 2 active not recruiting, 1 recruiting. 11 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 4, Unknown 3, Active not recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Unknown 3, Completed 1 |
Follow Leukemia, Prolymphocytic, B-Cell: new trials by email Literature Review of Leukemia, Prolymphocytic, B-Cell trials Research Report on Leukemia, Prolymphocytic, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies XmAb13676 - B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Xencor, Inc. | 154 | 2016-10-01 | 2024-11-13 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML ZEN003365 - Lymphoproliferative Malignancies, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Zenith Epigenetics | 2014-10-01 | 2014-11-13 | |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Ibrutinib, Lenalidomide - Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2013-04-26 | 2022-09-26 |
| Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies Nelarabine - Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 29 | 2010-06-08 | 2020-02-11 |
Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, Follicular (9) · Lymphoma, Mantle-Cell (9) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Non-Hodgkin (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Burkitt Lymphoma (3) · Leukemia, Hairy Cell (3) · Waldenstrom Macroglobulinemia (3) · Leukemia (2) · Lymphoma, B-Cell (2) · Anemia (1) · Leukemia, Biphenotypic, Acute (1)
Chronic Disease (11) · Disease Attributes (11) · Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Leukemia, B-Cell (11) · Leukemia, Lymphoid (11) · Leukemia, Prolymphocytic (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11)
Antigens, CD19 (3) · Sensitivity and Specificity (3) · Cyclophosphamide (2) · Immunotherapy, Adoptive (2) · fludarabine phosphate (2) · ibrutinib (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Bendamustine Hydrochloride (1) · Biopsy (1) · Blood Component Removal (1) · Etoposide (1) · Lenalidomide (1) · Leukapheresis (1) · Pharmacogenomic Variants (1) · Specimen Handling (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · City of Hope Medical Center (2) · Alexey Danilov, MD (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Sumithira Vasu (1) · Xencor, Inc. (1) · Zenith Epigenetics (1)
United States (8) · China (3) · France (1) · South Korea (1) · United Kingdom (1)
Alexey Danilov (1) · Chet Bohac, PharmD, MD, MSc (1) · Craig Okada, M.D. (1) · Daniel A Pollyea (1) · Lin Yang, Ph.D. (1) · Sumithira Vasu, MD (1) · Tanya Siddiqi (1) · Tapan Kadia, MD (1) · Xin Liu, Ph.D. (1) · Xingbing Wang, Ph.D. (1)
PMID 28054442, PMID 34196037, PMID 34492703, PMID 34515338, PMID 36448227, PMID 36631449
P30CA033572 (1), P30CA046934 (1), P30CA069533 (1), P50CA140158 (1), R01CA276374 (1), U01CA076576 (1), UM1CA186688 (1), UM1CA186712 (1)